Dopamine transporter deficiency syndrome

From WikiMD's WELLNESSPEDIA

Dopamine Transporter

Dopamine transporter deficiency syndrome (DTDS), also known as infantile parkinsonism-dystonia, is a rare genetic disorder that affects the dopamine transporter (DAT), a protein responsible for the reuptake of dopamine from the synapse back into the presynaptic neuron. This condition leads to a significant reduction in dopamine levels in the brain, resulting in severe motor and neurological symptoms.

Genetics[edit]

DTDS is caused by mutations in the SLC6A3 gene, which encodes the dopamine transporter protein. These mutations can lead to a loss of function of the transporter, impairing dopamine reuptake and causing an accumulation of dopamine in the synaptic cleft. The disorder is inherited in an autosomal recessive manner, meaning that an individual must inherit two copies of the mutated gene, one from each parent, to be affected.

Symptoms[edit]

The symptoms of DTDS typically appear in infancy or early childhood and may include:

Diagnosis[edit]

Diagnosis of DTDS is based on clinical evaluation, genetic testing, and the measurement of dopamine transporter function. Positron emission tomography (PET) scans can be used to assess the activity of the dopamine transporter in the brain. Genetic testing can confirm the presence of mutations in the SLC6A3 gene.

Treatment[edit]

There is currently no cure for DTDS, and treatment is primarily supportive and symptomatic. Management strategies may include:

Prognosis[edit]

The prognosis for individuals with DTDS varies depending on the severity of the symptoms and the effectiveness of the treatment. Early diagnosis and intervention can improve outcomes, but many individuals may experience significant motor and cognitive impairments throughout their lives.

See also[edit]

References[edit]


External links[edit]

-


Medical condition






















Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.